Investing Profile

Kanad Das

InvestorVC
Interim CBO SiteOne Therapeutics at SiteOne Therapeutics, Inc.
boehringer-ingelheim-venture....San Francisco, California
Photo of Kanad Das, SiteOne Therapeutics, Inc.

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Stanford University Network
121 CONNECTIONS
Genentech Network
21 CONNECTIONS
Merck Network
11 CONNECTIONS
cb
$3.3M - $17.0M
$8.5M
Interim CBO SiteOne Therapeutics SiteOne Therapeutics, Inc.2024 - Present
Venture Partner Bioluminescence Ventures2024 - 2025
Senior Director Bristol Myers Squibb2023 - 2024
Board Of Directors Libra Therapeutics2021 - 2023
Board of Directors Actym Therapeutics, Inc.2020 - 2023
Board of Directors OncoMyx Therapeutics2019 - 2023
Investment Director, Boehringer Ingelheim Venture Fund Boehringer Ingelheim2018 - 2023
Board of Directors Sentien Biotechnologies, Inc.2021 - 2021
Director, Business Development Merck2015 - 2018
Associate Director, SPARK Partnering and Alliance Management Stanford University2012 - 2015
Advisor SPARK Program2011 - 2012
Consultant Dermira, Inc.2011 - 2012
Senior Scientist KAI Pharmaceuticals2006 - 2010
Post-Doc Genentech2003 - 2006